Akero Therapeutics, Inc.
AKRONASDAQHealthcare
$54.65
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$58.4
52W Low$21.34
Akero Therapeutics, Inc.（AKRO）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · AKRO · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.74B | $0.55B | $0.35B | $0.19B | $0.27B |
| Net Receivables | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Inventory | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Assets | $0.77B | $0.56B | $0.36B | $0.19B | $0.27B |
| PP&E Net | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Goodwill | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Assets | $0.83B | $0.58B | $0.36B | $0.20B | $0.27B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Total Current Liabilities | $0.04B | $0.02B | $0.02B | $0.03B | $0.01B |
| Long-Term Debt | $0.04B | $0.02B | $0.01B | $0.00B | $0.00B |
| Total Liabilities | $0.08B | $0.04B | $0.03B | $0.03B | $0.01B |
| Stockholders Equity | |||||
| Retained Earnings | ($0.83B) | ($0.57B) | ($0.42B) | ($0.31B) | ($0.21B) |
| Total Stockholders Equity | $0.75B | $0.54B | $0.33B | $0.17B | $0.26B |
| Total Liab & Equity(computed) | $0.83B | $0.58B | $0.36B | $0.20B | $0.27B |
| Debt Summary | |||||
| Total Debt | $0.04B | $0.03B | $0.01B | $0.00B | $0.00B |
| Net Debt | ($0.30B) | ($0.21B) | ($0.24B) | ($0.15B) | ($0.19B) |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Akero Therapeutics, Inc.
关于Akero Therapeutics, Inc.（AKRO）资产负债表
Akero Therapeutics, Inc.总资产$0.83B，现金及短期投资$0.74B，总负债$0.08B，总债务$0.04B，股东权益$0.75B。
常见问题
AKRO · 4 问Akero Therapeutics, Inc.总债务$0.04B，净债务($0.30B)。
AKRO total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10